ישראל -
עברית -
Ministry of Health
ספירונולקטון טבע 25 מג
teva pharmaceutical industries ltd, israel - spironolactone - טבליה - spironolactone 25 mg - spironolactone - spironolactone - edematous conditions: - congestive heart failure; - cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.
ישראל -
עברית -
Ministry of Health
ספירונולקטון טבע 100 מג
teva pharmaceutical industries ltd, israel - spironolactone - טבליה - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.
ישראל -
עברית -
Ministry of Health
קווינאביק וטרינרי
abic veterinary products ltd - norfloxacin nicotinate 100 % - powder for solution - for the treatment of infections in chickens and turkeys caused by bacteria sensitive to norfloxacin, only after the sensitivity of the bacteria has been proven and it has been found that there is no alternative treatment (proven resistance to other agents).
ישראל -
עברית -
Ministry of Health
קווינאביק וטרינרי
abic veterinary products ltd - norfloxacin nicotinate 100 % - powder for solution - for the treatment of infections in chickens and turkeys caused by bacteria sensitive to norfloxacin, only after the sensitivity of the bacteria has been proven and it has been found that there is no alternative treatment (proven resistance to other agents).
ישראל -
עברית -
Ministry of Health
ניאספן 500 מ"ג טבליות מצופות בשחרור ממושך
abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n
ישראל -
עברית -
Ministry of Health
ניאספן 750 מ"ג טבליות מצופות בשחרור ממושך
abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n
ישראל -
עברית -
Ministry of Health
ניאספן 1000 מ"ג טבליות מצופות בשחרור ממושך
abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n